Trial Profile
Pilot Study for Measuring Molecular Biomarkers and Their Capacity to Characterize Radionuclide Therapy With Lu-177 DOTATATE) in Metastatic G1-G2 Neuroendocrine Midgut Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms GENEBIOLuNET
- 18 Sep 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2025.
- 18 Sep 2023 Planned primary completion date changed from 1 Aug 2021 to 1 Dec 2023.
- 18 Sep 2023 Status changed from recruiting to active, no longer recruiting.